Compare Pfizer Inc (PFE) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Teucrium Wheat Fund — how do they compare? Pfizer Inc trades at $27.72 (market cap $159.59B), while Teucrium Wheat Fund trades at $24.76 (market cap $279.74M). The key difference: Pfizer Inc is far larger — about 570.5× Teucrium Wheat Fund's market cap, and Pfizer Inc pays a 6.14% dividend while Teucrium Wheat Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Teucrium Wheat Fund for 40 Days on average.
| PFE | WEAT | |
|---|---|---|
Market Cap | $159.59B | $279.74M |
Volume | 30,937,010 | 210,079 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $29.02 | $28.00 |
52-Week Low | $23.67 | $19.88 |
Typical Hold Time | 158 Days | 40 Days |
Enterprise Value | $211.09B | — |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
WEAT trades at $24.9, down 2.31% over the past day amid a bearish technical signal from moving averages. The stock's technical indicators show neutral oscillators but selling pressure from the ADX. Recent news highlights WEAT's strong performance earlier in the year, with a 25% year-to-date gain as of July 2026, though inflation concerns persist as a market-wide theme.
The outlook for WEAT is cautious due to bearish technical momentum and macroeconomic headwinds from inflation. Investment opportunity exists if the stock holds key support levels, but risks include continued selling pressure and sensitivity to broader economic conditions. Investors should weigh technical weakness against the fund's earlier 2026 gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
